1. Resistin facilitates metastasis of lung adenocarcinoma through the TLR4/Src/EGFR/PI3K/NF‐κB pathway
   Wei‐Jing Gong et al, 2018, Cancer Science CrossRef
2. Phase I/II study of intermitted erlotinib in combination with docetaxel in patients with recurrent non-small cell lung cancer (WJOG4708L)
   Tatsuo Kimura et al, 2019, Japanese Journal of Clinical Oncology CrossRef
3. Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non–small lung cancer with EGFR TKIs-resistant mutation
   Feng Pan et al, 2011, Journal of Cancer Research and Clinical Oncology CrossRef
4. Intercalated Dosing Schedule of Erlotinib and Docetaxel as a Therapeutic Strategy to Avoid Antagonism and Optimize Its Benefits in Advanced Non–Small-Cell Lung Cancer. A Randomized Phase II Clinical Trial
   Óscar Juan et al, 2015, Clinical Lung Cancer CrossRef
5. Epidermal growth factor receptor status and Notch inhibition in non-small cell lung cancer cells
   Efstathia Giannopoulou et al, 2015, Journal of Biomedical Science CrossRef
6. Characterizing the malignancy and drug resistance of cancer cells from their membrane resealing response
   T. H. Hui et al, 2016, Scientific Reports CrossRef
7. Enhancement of gefitinib-induced growth inhibition by Marsdenia tenacissima extract in non-small cell lung cancer cells expressing wild or mutant EGFR
   Shu-Yan Han et al, 2014, BMC Complementary and Alternative Medicine CrossRef
8. Randomized phase III study of docetaxel versus docetaxel plus intercalated erlotinib in patients with relapsed non-squamous non-small cell lung carcinoma
   Christi M.J. Steendam et al, 2021, Lung Cancer CrossRef
9. Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung cancer: a phase I dose-finding study
   Seigo Minami et al, 2012, BMC Cancer CrossRef
10. The impact of competition between cancer cells and healthy cells on optimal drug delivery
    Heyrim Cho et al, 2020, Mathematical Modelling of Natural Phenomena CrossRef
11. Inhibition of the MUC1-C oncoprotein induces multiple myeloma cell death by down-regulating TIGAR expression and depleting NADPH
    Li Yin et al, 2012, Blood CrossRef
12. Erlotinib
    Emilie Petit-Jean et al, 2015, Therapeutic Drug Monitoring CrossRef
13. Dependence on the MUC1-C Oncoprotein in Non–Small Cell Lung Cancer Cells
    Deepak Raina et al, 2011, Molecular Cancer Therapeutics CrossRef
14. Schedule-dependent synergistic interaction between docetaxel and gefitinib in NSCLC cell lines regardless of the mutation status of EGFR and KRAS and its molecular mechanisms
    Yanwen Jiang et al, 2014, Journal of Cancer Research and Clinical Oncology CrossRef
15. Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts
    TOSHIKI IWAI et al, 2012, Oncology Reports CrossRef
16. [Ru(pipe)(dppb)(bipy)]PF6: A novel ruthenium complex that effectively inhibits ERK activation and cyclin D1 expression in A549 cells
    Guilherme A. Ferreira-Silva et al, 2017, Toxicology in Vitro CrossRef